COSM Cosmos Health Inc.
Company Updates ·
Cosmos Health said active U.S. subscriptions reached 8,940 as of October 19, 2026. It expects fourth-quarter U.S. revenue of approximately $15 million and gross profit of approximately $10.5 million. The figures are preliminary and unaudited.
Cosmos Health said preliminary revenue for the nine months ended September 30, 2026 was approximately $54.3 million, up 19%. The company reaffirmed its outlook for full-year 2026 revenue of more than $90 million.
Revenue rose 28.8% and total liabilities fell 13.3% from year-end 2025, the company said.
The program expires December 31, 2026 and may be renewed at the company's discretion.
Revenue rose 30.7% and total liabilities fell 9.6% in the quarter, and the company said its momentum continued into the second quarter.
Gross profit rose 83% to $7.90 million, and cash reached $3.46 million at December 31, 2025.
Cosmos Health said it could not finish its June 30, 2025 Form 10-Q on time, blaming delays in obtaining and compiling information, including its XBRL filing. It does not expect a significant change in results from a year earlier.
Cosmos Health agreed to issue up to $300 million of senior secured convertible promissory notes, with at least 72.5% of each tranche's net proceeds going to an Ethereum reserve. Curvature Securities, LLC was the sole placement agent, and the release gives no note terms or investor name.
Nasdaq gave the company until November 3, 2025 to lift its bid above $1.00 for 10 straight business days. The first 180-day period expired on May 5, 2025, and the release gives no plan beyond the CEO's stated confidence.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in Nevada in 2009. It owns proprietary pharmaceutical and nutraceutical brands, makes and distributes generics and healthcare products, conducts research and development on innovative medicines and drug repurposing, and operates a telehealth platform. Its markets include generic medicines, nutraceuticals, biocides, medical devices, novel oncology drugs, drug repurposing and telehealth services. Key proprietary brands named in the text are Sky Premium Life, Mediterranation and C-Sept and C-Scrub. Its growth strategy covers high-margin brands, generic pharmaceuticals, contract manufacturing and contract development and manufacturing, a global distribution network that includes the UAE and other GCC countries and Eastern Europe, and a corporate reorganization to reduce costs. Innovation programs named in the text include the CCX0722 obesity and weight management pill, CCDL24 for gastrointestinal disorders, and treatments for CNS, prostate, ovarian and colorectal cancers. The company also acquired Cloudscreen, an AI-driven drug repurposing platform.
| Product or program | What it is | Stage |
|---|---|---|
| CCX0722 | Obesity and weight management pill | |
| CCDL24 | Innovative treatment for gastrointestinal disorders | |
| Cloudscreen | AI-driven drug repurposing platform addressing several treatment areas | recently acquired |
| Sky Premium Life | Proprietary branded product line expanding into new fast growing regions | launches into new regions |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $65.3 million | $54.4 million |
| Research and development | $519,363 | $533,293 |
| Net income (loss) | -$19.1 million | -$16.2 million |
| Cash from operations | -$8.4 million | -$7.7 million |
| Cash and equivalents | $715,674 | $315,105 |
| Short-term investments | $46,158 | $21,148 |
Our latest story on this, dated Aug 6, 2025: "Cosmos Health signs note facility of up to $300 million for Ethereum treasury". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 30, 2026: "Cosmos Health authorizes share repurchase of up to $5 million". The story links the filing or release it is based on. Read the story.
Cosmos Health Inc. trades under the ticker COSM on NASDAQ.
Cosmos Health Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:V67A; LS:A3DZZN; LSX:A3DZZN.
The SEC Central Index Key (CIK) for Cosmos Health Inc. is 1474167. Its filings are on SEC EDGAR.
100,633,773 shares as of 2026-08-18, per the cover page of its 10-Q filed 2026-08-18.
Our directory records Cosmos Health Inc. under Greece.
Our directory classifies Cosmos Health Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cosmos Health Inc. is US2214133058.
aibio.space lists Cosmos Health Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in Nevada in 2009. It owns proprietary pharmaceutical and nutraceutical brands, makes and distributes generics and healthcare products, conducts research and development on innovative medicines and drug repurposing, and operates a telehealth platform.
CCX0722: Obesity and weight management pill Stage: not stated.
CCDL24: Innovative treatment for gastrointestinal disorders Stage: not stated.
$65.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Announced a share repurchase program. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio